Brokers Issue Forecasts for Stemline Therapeutics, Inc.’s Q3 2017 Earnings (STML)

Stemline Therapeutics, Inc. (NASDAQ:STML) – Equities research analysts at Wedbush decreased their Q3 2017 earnings per share (EPS) estimates for Stemline Therapeutics in a research report issued to clients and investors on Thursday. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings per share of ($0.62) for the quarter, down from their previous forecast of ($0.48). Wedbush currently has a “Outperform” rating and a $40.00 target price on the stock. Wedbush also issued estimates for Stemline Therapeutics’ Q4 2017 earnings at ($0.68) EPS, FY2017 earnings at ($2.63) EPS, Q1 2018 earnings at ($0.54) EPS, Q2 2018 earnings at ($0.54) EPS, Q3 2018 earnings at ($0.55) EPS, Q4 2018 earnings at ($0.53) EPS, FY2018 earnings at ($2.16) EPS, FY2019 earnings at ($1.30) EPS, FY2020 earnings at ($0.02) EPS and FY2021 earnings at $1.05 EPS.

A number of other equities research analysts have also recently commented on STML. Cowen and Company reiterated a “buy” rating on shares of Stemline Therapeutics in a report on Wednesday, June 14th. HC Wainwright set a $34.00 target price on Stemline Therapeutics and gave the company a “buy” rating in a report on Wednesday, August 9th. BidaskClub upgraded Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, July 19th. Jefferies Group LLC reiterated a “buy” rating and set a $16.00 target price on shares of Stemline Therapeutics in a report on Thursday, May 25th. Finally, Zacks Investment Research upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 20th. Two analysts have rated the stock with a sell rating and seven have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $29.17.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.com-unik.info/2017/08/16/brokers-issue-forecasts-for-stemline-therapeutics-inc-s-q3-2017-earnings-stml.html.

Stemline Therapeutics (STML) opened at 8.10 on Monday. The stock’s market cap is $189.99 million. Stemline Therapeutics has a 12 month low of $5.50 and a 12 month high of $14.60. The company’s 50-day moving average price is $9.25 and its 200-day moving average price is $8.44.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.18. The firm had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.30 million. Stemline Therapeutics had a negative return on equity of 67.35% and a negative net margin of 4,176.84%.

Hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC raised its position in shares of Stemline Therapeutics by 72.1% in the first quarter. FMR LLC now owns 2,538,892 shares of the biopharmaceutical company’s stock valued at $21,708,000 after buying an additional 1,063,457 shares during the period. AXA purchased a new position in shares of Stemline Therapeutics during the first quarter valued at $3,712,000. Sphera Funds Management LTD. purchased a new position in shares of Stemline Therapeutics during the first quarter valued at $2,565,000. Eventide Asset Management LLC raised its position in shares of Stemline Therapeutics by 27.6% in the first quarter. Eventide Asset Management LLC now owns 1,086,400 shares of the biopharmaceutical company’s stock valued at $9,289,000 after buying an additional 235,000 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Stemline Therapeutics by 32.9% in the first quarter. Vanguard Group Inc. now owns 825,153 shares of the biopharmaceutical company’s stock valued at $7,055,000 after buying an additional 204,228 shares during the period. 54.50% of the stock is currently owned by institutional investors and hedge funds.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Earnings History and Estimates for Stemline Therapeutics (NASDAQ:STML)

What are top analysts saying about Stemline Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stemline Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit